Chronic Obstructive Pulmonary Disease Clinical Trial
— CERAOfficial title:
A 6 Week Double-Blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of AZD1236as an Oral Tablet in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The primary aim of this study is to investigate the tolerability and safety of AZD 1236 compared with placebo ("inactive substance") in COPD patients by assessment of Adverse Events, vital signs and laboratory safety assessments.
Status | Completed |
Enrollment | 74 |
Est. completion date | March 2009 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of COPD for 1 month - Men or postmenopausal women - Spirometry values indicating reduced lung function - Smoking history equivalent to using 20 cigarettes a day for 10 years Exclusion Criteria: - Any current respiratory tract disorders other than COPD - Requirement for regular oxygen therapy - Use of oral or parenteral glucocorticosteroids within 30 days prior to the study |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Bulgaria | Research Site | Russe | |
Bulgaria | Research Site | Sofia | |
Finland | Research Site | Helsinki | |
Finland | Research Site | Oulu | |
Finland | Research Site | Preitila | |
Germany | Research Site | Berlin | |
Germany | Research Site | Grobhansdorf | |
Hungary | Research Site | Gyor | |
Hungary | Research Site | Komlo | |
Hungary | Research Site | Pecs | |
Hungary | Research Site | Vasarosnameny | |
Slovakia | Research Site | Bojnice | |
Slovakia | Research Site | Liptovsky Hradok | |
Slovakia | Research Site | Zilina |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
Bulgaria, Finland, Germany, Hungary, Slovakia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Adverse Events | Number of patients who had an Adverse Event | all study visits | Yes |
Secondary | Forced Expiratory Volume in 1 Second (FEV1) | Change in FEV1 from baseline to end of treatment | Before treatment and after 1, 2, 4 and 6 weeks of treatment | No |
Secondary | Forced Vital Capacity (FVC) | Change in FVC from baseline to end of treatment | Before treatment and after 1, 2, 4 and 6 weeks of treatment | No |
Secondary | Vital Capacity (VC) | Change in VC from baseline to end of treatment | Before treatment and after 1, 2, 4 and 6 weeks of treatment | No |
Secondary | Inspiratory Capacity (IC) | Change in IC from baseline to end of treatment | Before treatment and after 1, 2, 4 and 6 weeks of treatment | No |
Secondary | Forced Expiratory Flow (FEF)25-75% | Change in FEF from baseline to end of treatment | Before treatment and after 1, 2, 4 and 6 weeks of treatment | No |
Secondary | Peak Expiratory Flow (PEF) Morning | Change in PEF from average during run-in to average during the last 4 w of treatment | Daily during run-in and treatment | No |
Secondary | Peak Expiratory Flow (PEF) Evening | Change in PEF from average during run-in to average during the last 4 w of treatment | Daily during run-in and treatment | No |
Secondary | Clinical Chronic Obstructive Pulmonary Disease (COPD) Questionnaire(CCQ) Total | Change from baseline to end of treatment in score , The total scores vary between 0 (never/not limited at all) to 6 (almost all the time/totally limited) | Before treatment and after 1, 2, 4 and 6 weeks of treatment | No |
Secondary | Clinical Chronic Obstructive Pulmonary Disease (COPD) Symptoms, Breathlessness | Change in COPD symptom, Breathlessness from average during run-in to average during the last 4 w of treatment. 5-point Likert-type scale, ranging from 0 (none) to 4 (severe) | Daily during run-in and treatment | No |
Secondary | Clinical Chronic Obstructive Pulmonary Disease (COPD) Symptoms, Chest Tightness | Change in COPD symptom, chest tightness from average during run-in to average during the last 4 w of treatment, 5-point Likert-type scale, ranging from 0 (none) to 4 (severe) | Daily during run-in and treatment | No |
Secondary | Clinical Chronic Obstructive Pulmonary Disease (COPD) Symptoms, Cough Score | Change in COPD symptoms, cough score from average during run-in to average during the last 4 w of treatment, 5-point Likert-type scale, ranging from 0 (none) to 4 (severe) | Daily during run-in and treatment | No |
Secondary | Clinical Chronic Obstructive Pulmonary Disease (COPD) Symptoms, Night Time Awakenings | Change in night time awakenings from average during run-in to average during the last 4 w of treatment, 5-point Likert-type scale, ranging from 0 (none) to 4 (severe) | Daily during run-in and treatment | No |
Secondary | 6-minute Walk Test | Change from baseline to end of treatment | Before treatment and after 6 weeks of treatment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|